This CPB is revised to state that intravenous iron therapy is considered contraindicated and experimental and investigational for persons with genetic hemochromatosis or hemochromatosis secondary to iron overload. This CPB has been revised to state that intravenous iron therapy is considered experimental and investigational for treatment of acute mountain sickness.